Profile data is unavailable for this security.
About the company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
- Revenue in USD (TTM)80.83m
- Net income in USD-87.16m
- Incorporated2020
- Employees242.00
- LocationImmatics NVPaul Ehrlich-Strasse 15TUEBINGEN 72076GermanyDEU
- Phone+49 70 715397700
- Websitehttps://immatics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | 35.33m | -329.12m | 1.00bn | 309.00 | -- | 1.34 | -- | 28.41 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Innoviva Inc | 311.59m | 181.39m | 1.01bn | 112.00 | 7.37 | 1.44 | 4.59 | 3.24 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Liquidia Corp | 15.97m | -107.69m | 1.01bn | 136.00 | -- | 11.72 | -- | 63.39 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.07bn | 29.00 | -- | 12.25 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.08bn | 46.00 | -- | 3.37 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.08bn | 267.00 | -- | -- | -- | 2.61 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Immatics NV | 80.83m | -87.16m | 1.09bn | 242.00 | -- | 2.52 | -- | 13.54 | -1.06 | -1.06 | 0.9395 | 4.22 | 0.1444 | -- | 74.03 | 334,006.90 | -15.57 | -30.79 | -20.54 | -46.06 | -- | -- | -107.83 | -127.58 | -- | -- | 0.0352 | -- | -68.76 | -- | -358.55 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.10bn | 296.00 | -- | 4.87 | -- | 10.31 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Pharvaris NV | 0.00 | -115.34m | 1.11bn | 82.00 | -- | 2.84 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Silence Therapeutics plc | 33.56m | -44.40m | 1.11bn | 115.00 | -- | 6.20 | -- | 33.14 | -0.3901 | -0.3901 | 0.2849 | 1.13 | 0.1829 | -- | 5.37 | 291,785.10 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 1.12bn | 593.00 | -- | 19.76 | -- | 7.97 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.13bn | 197.00 | 16.76 | 5.08 | 4.71 | 1.99 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.13bn | 586.00 | -- | 1.00 | -- | 31.63 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.16bn | 173.00 | -- | 2.31 | -- | 13.04 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Data as of May 22 2024. Currency figures normalised to Immatics NV's reporting currency: US Dollar USD
46.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 10.00m | 9.71% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 8.33m | 8.09% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 6.44m | 6.26% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 6.30m | 6.12% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 4.58m | 4.45% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.23m | 3.13% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.82m | 2.74% |
| Woodline Partners LPas of 31 Mar 2024 | 2.37m | 2.31% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.81m | 1.76% |
| RA Capital Management LPas of 31 Mar 2024 | 1.75m | 1.70% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
